Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02650999
Title Study of Pembrolizumab in Patients Failing to Respond to or Relapsing After Anti-CD19 Chimeric Antigen Receptor Modified T Cell Therapy for Relapsed or Refractory CD19+ Lymphomas
Recruitment Completed
Gender female
Phase Phase Ib/II
Variant Requirements No
Sponsors Abramson Cancer Center of the University of Pennsylvania
Indications
Therapies
Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
Abramson Cancer Center of the University of Pennsylvania Philadelphia Pennsylvania 19104 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field